cyc 202 has been researched along with tamoxifen in 6 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (tamoxifen) | Trials (tamoxifen) | Recent Studies (post-2010) (tamoxifen) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 20,630 | 2,227 | 6,256 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Maurer, M; Wesierska-Gadek, J; Zulehner, N | 1 |
| Gritsch, D; Maurer, M; Wesierska-Gadek, J; Zulehner, N | 1 |
| Gritsch, D; Komina, O; Maurer, M; Węsierska-Gądek, J; Zulehner, N | 2 |
6 other study(ies) available for cyc 202 and tamoxifen
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Effect of anti-estrogen combined with roscovitine, a selective CDK inhibitor, on human breast cancer cells differing in expression of ER.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinases; Estrogen Receptor alpha; Female; Flow Cytometry; G1 Phase; G2 Phase; Humans; Immunoblotting; Purines; Roscovitine; Tamoxifen; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Tamoxifen enhances the anti-proliferative effect of roscovitine, a selective cyclin-dependent kinase inhibitor, on human ER-positive human breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclin-Dependent Kinases; Drug Synergism; Estrogen Receptor alpha; Flow Cytometry; G1 Phase; Humans; Immunoblotting; Multiple Myeloma; Purines; Roscovitine; S Phase; Tamoxifen; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells.
Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Synergism; Estrogen Receptor alpha; Flow Cytometry; G2 Phase; HeLa Cells; Humans; Immunoblotting; Membrane Potential, Mitochondrial; Phosphorylation; Protein Kinase Inhibitors; Purines; Roscovitine; Selective Estrogen Receptor Modulators; Serine; Tamoxifen; Time Factors | 2011 |
Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinases; Dichlororibofuranosylbenzimidazole; Drug Synergism; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Humans; Neoplasms, Hormone-Dependent; Phosphorylation; Purines; RNA Polymerase II; Roscovitine; Tamoxifen; Tumor Suppressor Protein p53 | 2011 |